Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Upgraded by The Goldman Sachs Group to “Strong-Buy” Rating

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was upgraded by stock analysts at The Goldman Sachs Group from a “hold” rating to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Separately, Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR currently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

SGIOY opened at $8.85 on Monday. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. Shionogi & Co., Ltd. Unsponsored ADR has a 52-week low of $7.65 and a 52-week high of $12.00. The company has a 50 day moving average of $9.70 and a two-hundred day moving average of $9.89. The company has a market cap of $15.06 billion, a P/E ratio of 11.06, a P/E/G ratio of 3.32 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. The company had revenue of $881.71 million during the quarter, compared to analyst estimates of $895.52 million. On average, analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.